# LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma

> **NCT03684980** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 58 (actual)

## Conditions studied

- Central Nervous System Lymphoma

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Rituximab
- **DRUG:** leucovorin
- **DRUG:** Glucarpidase

## Key facts

- **NCT ID:** NCT03684980
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-14
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03684980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03684980, "LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03684980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*